NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”) (NASDAQ: INFI) concerning possible violations of federal securities laws.
On June 14, 2016, Infinity announced a restructuring that would reduce its workforce by 21% in the wake of disappointing drug-study results. While a Phase 2 study of its treatment for non-Hodgkin lymphoma met its primary endpoint of overall response rate, the Company said it hoped it would provide a larger clinical benefit. Upon this news, shares of Infinity were down more than 69% on intraday trading. To obtain additional information about the investigation, go to:
or contact Eduard Korsinsky, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.